Project Grant R42CA291346
Award Date
6/9/25
Completion Date
5/31/26
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60616, USA
Similar Awards
This $400,000 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel, RNA interference-based therapeutic to treat prostate cancer by Nuago Therapeutics, Inc. The therapeutic approach involves delivering short interfering RNA (siRNA) molecules derived from CAG trinucleotide repeat sequences, which have been shown to be toxic to cancer cells. This Phase I project will evaluate the uptake and activity of the siRNA-based...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) is funding research to develop a novel cancer therapy with both immuno-activating and oncology-targeting capabilities to treat triple negative breast cancer. The $661,072 award to Northwestern University, with a subcontract to Exomira Medicine Inc., aims to advance an IND-enabling study for a first-in-class small molecule inhibitor targeting the USP22 oncogene. This multifaceted approach...
This $546,625 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) is focused on developing a novel immunochemotherapy approach for treating metastatic colorectal cancer (mCRC). The key products and services to be delivered under this 5-year award (1/9/2025 - 12/31/2029) include: Developing and characterizing a nanocarrier platform (PCL-CP) capable of co-delivering siRNA targeting the IRHOM1 gene and a prodrug conjugate of camptothecin...
The National Cancer Institute (NCI) awarded a $399,214 Project Grant under CFDA 93.395 - Cancer Treatment Research to Proton Bio, Inc., a minority-owned business located in Baltimore, Maryland. The grant supports a 12-month project to develop and evaluate a novel therapy targeting the proton-sensing receptor GPR68 as a potential treatment for glioblastoma (GBM), the most common and aggressive form of adult brain cancer. The project will focus on three key objectives: 1) define the in vitro...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
The U.S. National Cancer Institute awarded a $644,034 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The General Hospital Corporation (Massachusetts General Hospital) to develop a nanoparticle-based drug delivery platform that utilizes radiation therapy to enable sustained and localized release of chemotherapy within irradiated tumor tissues. The goal is to improve the therapeutic window of chemoradiation by enhancing local disease control while mitigating systemic toxicities. The...
The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging and Dosimetry, LLC, a for-profit company based in Baltimore, Maryland. The grant funding will support the development of a prototype web/cloud-based quantitative SPECT reconstruction software system to enable precise imaging and dosimetry for emerging radiopharmaceutical cancer therapies, particularly those utilizing alpha-emitting...
The National Cancer Institute awarded a $1,078,680 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Nerx Biosciences Inc., a small disadvantaged business located in Indianapolis, Indiana. The goal of this 2-year award, effective August 1, 2024, is to accelerate the commercial readiness of NERX-329, a novel small molecule inhibitor that disrupts the DNA damage response (DDR) sensor replication protein A (RPA). This inhibitor represents a first-in-class approach to targeting the DDR...
The National Cancer Institute (NCI) has awarded a $435,773 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Maryland, Baltimore (UMB) to develop an engineered prodrug capable of selectively delivering potent cytotoxins to malignant tumor cells. The goal is to leverage hyperactive membrane-anchored serine proteases (MASPs) on the surface of tumor cells to activate the prodrug and selectively kill cancer cells, particularly in ovarian, lung, and colon cancers. The...
This $400,000 Project Grant award from the National Cancer Institute's (CFDA 93.395) Cancer Treatment Research program aims to activate the transcription factor EB (TFEB) in order to enhance the efficacy of immunotherapy for triple-negative breast cancer (TNBC). The funded research will evaluate the toxicity and pharmacokinetic properties of the TFEB activator compound USCYL01, as well as test its ability to improve the efficacy of immune checkpoint inhibitor (ICI) therapy combined with...